Share Price, page-8007

I'm on the right track !!! Ridiculous!!!

Key Pipeline Updates:

• Alzheimer’s disease: Full data from the blarcamesine in Alzheimer’s disease Phase 2b/3 randomized clinical trial will be published in an upcoming peer-reviewed journal. The Company has initiated the process for submitting a Marketing Authorisation application to the European Medicines Agency (EMA) under the Centralised Procedure. The Marketing Authorisation would allow direct market access throughout the European Union for oral blarcamesine for the treatment of Alzheimer’s disease. There are an estimated 7 million people in Europe with Alzheimer’s disease, a number expected to double by 2030, according to the European Brain Council.[1]
• Alzheimer’s disease: Ongoing ATTENTION-AD open-label extension 96-week trial.
• Rett syndrome: On track for top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial.
• Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused trial and Phase 2b/3 6 months trial.
• Schizophrenia: Initiation of ANAVEX®3-71 Phase 2 clinical trial.
• Fragile X: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial.
• New Rare disease: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial.
• Publications: Continued clinical publications involving ANAVEX®2-73 and ANAVEX®3-71.

https://www.anavex.com/post/anavex-...inancial-results-and-provides-business-update